A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances Dendritic Cells-Based Tumor Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seung Jun | - |
dc.contributor.author | Shin, Sung Jae | - |
dc.contributor.author | Lee, Moon Hee | - |
dc.contributor.author | Lee, Min-Goo | - |
dc.contributor.author | Kang, Tae Heung | - |
dc.contributor.author | Park, Won Sun | - |
dc.contributor.author | Soh, Byoung Yul | - |
dc.contributor.author | Park, Jung Hee | - |
dc.contributor.author | Shin, Yong Kyoo | - |
dc.contributor.author | Kim, Han Wool | - |
dc.contributor.author | Yun, Cheol-Heui | - |
dc.contributor.author | Jung, In Duk | - |
dc.contributor.author | Park, Yeong-Min | - |
dc.date.available | 2019-03-08T21:37:25Z | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11930 | - |
dc.description.abstract | A key factor in dendritic cell (DC)-based tumor immunotherapy is the identification of an immunoadjuvant capable of inducing DC maturation to enhance cellular immunity. The efficacy of a 50S ribosomal protein L7/L12 (rplL) from Mycobacterium tuberculosis Rv0652, as an immunoadjuvant for DC-based tumor immunotherapy, and its capacity for inducing DC maturation was investigated. In this study, we showed that Rv0652 is recognized by Toll-like receptor 4 (TLR4) to induce DC maturation, and pro-inflammatory cytokine production (TNF-alpha, IL-1beta, and IL-6) that is partially modulated by both MyD88 and TRIF signaling pathways. Rv0652-activated DCs could activate naive T cells, effectively polarize CD4(+) and CD8(+) T cells to secrete IFN-gamma, and induce T cell-mediated-cytotoxicity. Immunization of mice with Rv0652-stimulated ovalbumin (OVA)-pulsed DCs resulted in induction of a potent OVA-specific CD8(+) T cell response, slowed tumor growth, and promoted long-term survival in a murine OVA-expressing E. G7 thymoma model. These findings suggest that Rv0652 enhances the polarization of T effector cells toward a Th1 phenotype through DC maturation, and that Rv0652 may be an effective adjuvant for enhancing the therapeutic response to DC-based tumor immunotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.title | A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances Dendritic Cells-Based Tumor Immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1371/journal.pone.0104351 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.9, no.8 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000339993900059 | - |
dc.identifier.scopusid | 2-s2.0-84905457093 | - |
dc.citation.number | 8 | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | TOLL-LIKE RECEPTORS | - |
dc.subject.keywordPlus | CANCER-IMMUNOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA-CELLS | - |
dc.subject.keywordPlus | MELANOMA PATIENTS | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | INNATE IMMUNITY | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | FUSIONS | - |
dc.subject.keywordPlus | ANTIGEN | - |
dc.subject.keywordPlus | MICE | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.